Literature DB >> 1676428

Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases.

A Gazit1, N Osherov, I Posner, P Yaish, E Poradosu, C Gilon, A Levitzki.   

Abstract

We have previously described a novel series of low molecular weight protein tyrosine kinase inhibitors which we named tyrphostins. The characteristic active pharmacophore of these compounds was the hydroxy-cis-benzylidenemalononitrile moiety. In this article we describe three novel groups of tyrphostins: (i) one group has the phenolic moiety of the cis-benzylidenemalononitrile replaced either with other substituted benzenes or with heteroaromatic rings, (ii) another is a series of conformationally constrained derivatives of hydroxy-cis-benzylidenemalononitriles in which the malononitrile moiety is fixed relative to the aromatic ring, and (iii) two groups of compounds in which the position trans to the benzenemalononitrile has been substituted by ketones and amides. Among the novel tyrphostins examined we found inhibitors which discriminate between the highly homologous EGF receptor kinase (HER1) and ErbB2/neu kinase (HER2). These findings may lead to selective tyrosine kinase blockers for the treatment of diseases in which ErbB2/neu is involved.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676428     DOI: 10.1021/jm00110a022

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  37 in total

1.  In vivo analysis of compound activity and mechanism of action using epistasis in Drosophila.

Authors:  Erdem Bangi; Dan Garza; Marc Hild
Journal:  J Chem Biol       Date:  2010-12-22

Review 2.  Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.

Authors:  Pushpendra Singh; Jimi Marin Alex; Felix Bast
Journal:  Med Oncol       Date:  2013-12-14       Impact factor: 3.064

3.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

Review 4.  Role of tyrosine kinases in lymphocyte activation: targets for drug intervention.

Authors:  J H Hanke; B A Pollok; P S Changelian
Journal:  Inflamm Res       Date:  1995-09       Impact factor: 4.575

Review 5.  Advances in immunosuppression for renal transplantation.

Authors:  Antoine Durrbach; Helene Francois; Severine Beaudreuil; Antoine Jacquet; Bernard Charpentier
Journal:  Nat Rev Nephrol       Date:  2010-02-02       Impact factor: 28.314

6.  Substrate specificity and inhibitor profile of human recombinant p56lck from a baculovirus expression vector.

Authors:  H Flotow; T J Purton; D P Whitaker; D H Williams; S E Wilkinson
Journal:  Inflamm Res       Date:  1996-08       Impact factor: 4.575

7.  Protein kinase C requirement of Ca2+ channel stimulation by intracellular ATP in guinea-pig basilar artery smooth muscle cells.

Authors:  D McHugh; D J Beech
Journal:  J Physiol       Date:  1997-04-15       Impact factor: 5.182

8.  Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis.

Authors:  J E Sevransky; G Shaked; A Novogrodsky; A Levitzki; A Gazit; A Hoffman; R J Elin; Z M Quezado; B D Freeman; P Q Eichacker; R L Danner; S M Banks; J Bacher; M L Thomas; C Natanson
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

9.  Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression.

Authors:  Matthew D Christensen; Jacob J Elmer; Seron Eaton; Laura Gonzalez-Malerva; Joshua LaBaer; Kaushal Rege
Journal:  J Control Release       Date:  2015-02-11       Impact factor: 9.776

10.  Tyrphostin ErbB2 Inhibitors AG825 and AG879 Have Non-specific Suppressive Effects on gp130/ STAT3 Signaling.

Authors:  Hyun Kyoung Lee; In Ae Seo; Sang Hwa Lee; Su-Young Seo; Kyung Sup Kim; Hwan Tae Park
Journal:  Korean J Physiol Pharmacol       Date:  2008-10-31       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.